Antiangiogenic therapy for breast cancer

Breast Cancer Research

Volumn 12, Issue 5, 2010, Pages

  Nielsen, Dorte Lisbet ^a   Andersson, Michael ^a   Andersen, Jon Lykkegaard ^a   Kamby, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; BEVACIZUMAB; INDOLE DERIVATIVE; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE; SORAFENIB; SUNITINIB; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZENESULFONATES; BREAST NEOPLASMS; FEMALE; HUMANS; INDOLES; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRROLES; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858681818     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2642     Document Type: Review

References (113)

1. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006, 96:223-268.
2. Schneider BP, Sledge GW. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007, 4:181-189. 10.1038/ncponc0740, 17327858.
3. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40. 16407877, 10.1038/ncponc0403.
4. Ferrara N, Hillan K, Gerber H-P, Novotny W. Discovery and development of bevacizumab, an anti VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-398. 10.1038/nrd1381, 15136787.
5. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Nototny WF, Reiman JD, Vassel A. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003, 30(5 Suppl 16):117-124. 10.1053/j.seminoncol.2003.08.013, 14613032.
6. Ramaswamy B, Elias AD, Kelbick NT, Dodley A, Morrow M, Hauger M, Allen J, Roades C, Kendra K, Chen HX, Eckhardt SG, Shapiro CL. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006, 12:3124-3129. 10.1158/1078-0432.CCR-05-2603, 16707611.
7. Chan D, Allen H, Hu E, Reese D, Patel G, Gottlieb C, Wax A, Sosa J, Slamon D, Kabbinavar F. Phase II study of docetaxel (D) plus bevacizumab (B) in Her2 negative metastatic breast carcinoma. J Clin Oncol 2006, 24(June 20 Supplement):abstract 13047.
8. Hurvitz SA, Kabbinavar FF, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Reese D, Slamon DJ. A phase II trial of docetaxel with bevacizumab as first line therapy for Her2/neu negative metastatic breast carcinoma. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 4062.
9. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kananic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Ann Oncol 2010, 21:269-274. 10.1093/annonc/mdp512, 19901014.
10. Hoelzer KL, Brufsky A, Hainsworth J, Beck JT, Whorf R, Keaton M, Kroener J, Krill-Jackson E, Hu S, Bromund J. Preliminary results of a randomized phase II study of paclitaxel and bevacizumab ± gemcitabine as first-line treatment for metastatic breast cancer. J Clin Oncol 2009, 27(15S):abstract 1089.
11. Guardino AE, Chen M, Levy M, Chen M. Phase II trial with gemcitabine, paclitaxel and bevacizumab for the first line treatment of metastatic breast cancer. Cancer Res 2009, 69(Suppl):abstract 6089.
12. Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S):abstract 1029.
13. Danso MA, Blum JL, Robert NJ, Krekow L, Rotche R, Smith DA, Richards P, Anderson T, Richards DA, O'Shaughnessy J. Phase II trial of weekly nabpaclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. J Clin Oncol 2008, 26(May 20 Suppl):abstract 1075.
14. Conlin AK, Hudis CA, Bach A, Moynaha M, Lake D, Forero-Torres A, Wright G, Hackney M, Claws A, Seidman AD. Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S):abstract 1006.
15. Sledge G, Miller K, Moisa C, Gradisar W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 2007, 25(18S):abstract 1013.
16. Traina TA, Theodoulou M, Dugan U, Feigin K, Patil S, Geneus S, Godfrey L, Norton L, Hudis C. A novel capecitabine dosing schedule combined with bevacizumab is safe and active in patients with metastatic breast cancer: a phase II study. Cancer Res 2009, 69(Suppl 2):abstract 6121.
17. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008, 26:4899-4905. 10.1200/JCO.2008.17.4789, 18794539.
18. Rochlitz C, Spirig C, Ruhstaller T, Suter T, Bühlmann M, Fehr M, Schönenberger A, Lerch S, Mayer M, Zaman K. Bevacizumab and pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer: a multicenter, single-arm phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2009, 27(15S):abstract 1030.
19. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reiman JD, Sing AP, Langmuir V, Rugo HS. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799. 10.1200/JCO.2005.05.098, 15681523.
20. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676. 10.1056/NEJMoa072113, 18160686.
21. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Scheeweiss A, Wardley AM, Chlistalla A, Romieu G. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:3239-3247. 10.1200/JCO.2008.21.6457, 20498403.
22. Robert N, Dieras V, Glaspy J, Brufsky A, Bondarenko I, Lipatov O, Perez E, Yardley D, Zhou X. RIBBON-1: a randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009, 27(15S):abstract 1005.
23. O'Shaughnessy J, Miles D, Gray J, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15S):abstract 1005.
24. Brufsky A, Bondarenko IN, Smirnov V, Hurvitz SA, Perez EA, Ponovarova O, Vynnychenko I, Swamy R, Mu H, Rivera RR. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009, 69(Suppl):abstract 42.
25. Brufsky A, Rivera RR, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, Rugo HS, Swamy R, Mu H, Perez EA. Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2010, 28(15S):abstract 1021.
26. Falkson C, Rossman JF, Nabell L, Carpenter J, Forero A, Kim Y, Saleh M. A phase II trial investigating if bevacizumab in combination with hormone therapy reverse acquired estrogen indepence in metastatic breast cancer patients. J Clin Oncol 2009, 27(15S):abstract e12027.
27. Traina TA, Rugo H, Caravelli JF, Yeh B, Panageas K, Bruckner J, Norton L, Park J, Hudis C, Dickler M. Letrozole (L) with bevacizumab (B) is feasible in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC). J Clin Oncol 2006, 24(18S):abstract 3050.
28. Rubin MS, Barton J, Shipley D, Arrowsmith E, Peacock N, Hart L, Evans J, Vasquez E, Burris HA, Yardley D. Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. J Clin Oncol 2009, 27(15S):abstract 1091.
29. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Nothfeldt D, Lingle W, Copland J, Perez EA. N0539 Phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group trial. Cancer Res 2009, 69(Suppl):abstract 4096.
30. Hurvitz SA, Bosserman LD, Leland-Jones B, Thirwell M, Allison MK, Barstis J, Molthrop D, Quan E, Upadhyaya G, Slamon D. A multicenter, double-blind randomized phase II trial of neoadjuvant treatment with single-agent bevacizumab or placebo, followed by docetaxel, doxorubicin, and cyclophosphamide (TAC), with or without bevacizumab, in patients with stage II or III breast cancer. J Clin Oncol 2008, 26(May 20 Suppl):abstract 562.
31. Makhoul I, Klimberg S, Henry-Tillman R, Westbrook K, Korourian S, Siegel E, Hutchins L. Primary systemic therapy using docetaxel/cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC). Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 5055.
32. Greil R, Moik M, Reitsamer R, Ressler S, Stoll M, Namberger K, Menzel C, Mlineritsch B. Capecitabine + docetaxel + bevacizumab as neoadjuvant therapy for invasive breast cancer: results of a phase II pilot study. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 4064.
33. Balduzzi A, Montagna E, Bagnardi V, Torrisi R, Mancuso P, Scarano E, Viale G, Veronesi P, Cardillo A, Orlando L, Goldhirsch A, Colleoni M. Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavourable prognostic features. Anticancer Drugs 2009, 20:197-203. 10.1097/CAD.0b013e3283264719, 19182679.
34. Wedam SB, Low JA, Yang SX, Chow CK, Choyke P, Danforth D, Hewitt SM, Berman A, Steinberg SM, Liewehr DJ, Plehn J, Doshi A, Thomasson D, McCarthy N, Koeppen H, Sherman M, Zujewski J, Camphausen K, Chen H, Swain SM. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006, 24:769-777. 16391297, 10.1200/JCO.2005.03.4645.
35. Lyons JA, Silverman P, Remick S, Chen H, Leeming R, Shenk R, Fu P, Dumadag L, Escuro K, Overmoyer B. Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. J Clin Oncol 2006, 24(18S):abstract 3049.
36. Raefsky E, Castillo R, Lahity A, Thompson DS, Hanson S, Meng C, Knauer D, Trieu V, Desai N, Yardley DA. Phase II study of neoadjuvant bevacizumab and trastuzumab administrated with albumin-bound paclitaxel (nab paclitaxel) and carboplatin in HER2+ locally advanced breast cancer. J Clin Oncol 2008, 26(May 20 Suppl):abstract 627.
37. Locatelli MA, Curigliano G, Fumagalli L, Ghisini R, Mancuso P, Bertolini F, Viale G, Lunghi L, Goldhirsch A. Bevacizumab and oral chemotherapy for patients with lymphangitis breast cancer: a phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. J Clin Oncol 2009, 27(15S):abstract 1031.
38. Torrisi R, Bagnardi V, Cardillo A, Bertolini F, Scarano E, Orlando L, Mancuso P, Luini A, Calleri A, Viale G, Goldhirsch A, Colleoni M. Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008, 99:1564-1571. 18941458, 10.1038/sj.bjc.6604741, 2584958.
39. Forero-Torres A, Galleshaw J, Jones C, Percent I, Nabell L, Carpenter J, Falkson C, Krontiras H, Bland K, De Los Santos J, Saleh MN. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J Clin Oncol 2008, 26(May 20 Suppl):abstract 652.
40. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph nodepositive breast cancer: a trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008, 26(May 20 Suppl):abstract 520.
41. Hart LL, Badarinath S, Waterhouse DM, Daniel B, Raimondo D, Burris HA, Yardley DA. A multicenter study of 3 docetaxel regimens with bevacizumab as adjuvant therapy for breast cancer (BC): preliminary results. J Clin Oncol 2008, 26(May 20 Suppl):abstract 575.
42. Mayer EL, Miller KD, Rugo HS, Peppercorn JM, Carey LA, Ryabin N, Winer EP, Burstein HJ. A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol 2007, 25(18S):abstract 561.
43. Sanborn RE, Sandler A. The safety of bevacizumab. Expert Opin Drug Saf 2006, 5:289-301. 10.1517/14740338.5.2.289, 16503749.
44. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Loffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002, 99:11393-11398. 10.1073/pnas.172398299, 123267, 12177445.
45. Hobday TJ, Rowland K, Dueck A, Northfelt D, Lingle W, Morton R, Fitch T, Nikcevich D, Perez EA. N0537: A North Central Cancer Group (NCCTG) phase II trial of VEGF trp in patients with metastatic breast cancer (MBC) previously treated with an anthracycline and/or a taxane. J Clin Oncol 2008, 26(May 20 Suppl):abstract 164.
46. Chen Q, Manning CD, Millar H, McCabe FL, Ferrante C, Sharp C, Shahied-Arruda L, Doshi P, Nakada MT, Anderson GM. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cell lines. Clin Exp Metastasis 2008, 25:139-148. 10.1007/s10585-007-9132-4, 18064530.
47. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Kock M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmelit P. Anti-PIGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475. 10.1016/j.cell.2007.08.038, 17981115.
48. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007, 25:884-896. 10.1200/JCO.2006.06.3602, 17327610.
49. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD. Phase II study of sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008, 26:1810-1816. 18347007, 10.1200/JCO.2007.14.5375.
50. Lyandres J, Melisko M, Moasser M, Goga A, Park JW, Rugo HS. Phase I study of sunitinib in combination with metronomic dosing of cyclophosphamide and methotrexate in patients with metastatic breast cancer. Cancer Res 2009, 69(Suppl 2):abstract 4119.
51. Gianni L, Cardoso F, Mariani G, Isaksson-Friman E, Besse-Hammer T, Vigano L, Verkh L, Rossi C, Giorgetti C, Bergh J. Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6079.
52. Kozloff MF, Chuang E, Roy J, Starr A, Gowland PA, Tarpey MJ, Collier M, Verk L, Miller K. A phase I study of sunitinib plus paclitaxel for first-line treatment af advanced breast cancer: preliminary results. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6078.
53. Wildiers H, Fontaine C, Vuylsteke P, Martens M, Canon J-L, Wynendaele W, Focan C, Degreve J, Paridaens R. SUCON trial (SUnetinib CONsolidation therapy in metastatic breast cancer): a Belgian multicenter phase II randomized trial in Her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with sunitinib after objective response to taxane chemotherapy. Cancer Res 2009, 69(Suppl):abstract 203.
54. Bergh J, Greil R, Voytko N, Makhson A, Cortes J, Lortholary A, Huang X, Giorgetti C, Kern KA, Lichinitser M. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol 2010, 28(15S):abstract LBA1010.
55. Crown J, Dieras V, Staroslawska E, Yardley DA, Davidson N, Bachelot TD, Tassell TR, Huang X, Kern KA, Romieu G. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010, 28(15S):abstract LBA1011.
56. Barrios C, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, Pivot X, Iwata H, Aogi K, Lugo-Quintana R, Harbeck N, Brickman MJ, Zhang K, Zhang K, Kern KA, Martin M. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 2010, 121:121-131. 10.1007/s10549-010-0788-0, 2855860, 20339913.
57. Chu TF, Rupnick M, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, van den Abbeele AD, Demetri GD, Force T, Chen MH. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019. 10.1016/S0140-6736(07)61865-0, 2643085, 18083403.
58. Strumberg D. Preclinical and clinical development of the oral multikinase sorafenib in cancer treatment. Drugs Today (Barc) 2005, 41:773-784. 10.1358/dot.2005.41.12.937959, 16474853.
59. Bianchi GV, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Penña C, Lathia C, Bergamini L, Gianni L. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs 2009, 20:616-624. 10.1097/CAD.0b013e32832b2ea0, 19739318.
60. Baselga J, , Roché H, Costa F, Getulio JMS, Pinczowski H, Ma EC, Cabral SF, Gomez P, van Eyll B. Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólido SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafinib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res 2009, 69(Suppl):abstract 45. Grupo Espanol de Estudio Tratamiento y Otras Estrategias Experimentales en Tumores Sólido.
61. Gradishar WJ, Kaklamani V, Prasad TS, Lokanatha D, Raina V, Bondarde S, Jain M, Schwartzberg L. A double-blind, randomized, placebo-controlled, phase 2b study evaluating the efficacy and safety of sorafenib (SOR) in combination with paclitaxel (PAC) as a first-line therapy in patients (pts) with locally recurrent or metastatic breast cancer. Cancer Res 2009, 69(Suppl):abstract 44.
62. Sonpavde G, Hudson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007, 9:115-119. 10.1007/s11912-007-0007-2, 17288876.
63. Taylor SK, Chia S, Dent S, Clemons M, Grenci P, Wang L, Oza AM, Ivy P, Pritchard K, Leighl N. A phse II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009, 27(15S):abstract 1133.
64. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
65. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
66. Miller KD, Trigo JM, Wheeler C, Baarge A, Rowbottom J, Sledge G, Baselga J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005, 11:3369-3376. 10.1158/1078-0432.CCR-04-1923, 15867237.
67. Boér K, Láng I, Liombart-Cussac A, Andreasson I, Vivanco GL, Sanders N, Pover GM, Murray E. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized phase II study. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6081.
68. Rosen LS, Kurzrock R, Mulay M, van Vugt A, Purdom M, Ng C, Silverman J, Koutsoukos A, Sun YN, Bass MB, Xu RY, Polverino A, Wiezorek JS, Chang DD, Benjamin R, Herbst RS. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007, 25:2369-2376. 10.1200/JCO.2006.07.8170, 17557949.
69. de Boer R, White S, Mainwaring P, Koczwara B, Ye Y, Sun Y-N, Parson M, Braun A, Kotasek D. Safety and pharmacokinetics of motesanib diphosphate (AMG 706) with paclitaxel or doxorubicin for the treatment of locally recurrent, unresectable or metastatic breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6074.
70. Choueiri TK. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. Curr Opin Investig Drugs 2008, 9:658-671.
71. Rugo HS, Stopeck A, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Soulieres D. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). J Clin Oncol 2007, 25(18S):abstract 1003.
72. Nickoloff BJ, Osborne BA, Miele L. Notch signalling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 2003, 22:6598-6608. 10.1038/sj.onc.1206758, 14528285.
73. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YC, Evelhoch JL, Oliner JD, Le N, Rosen LS. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced tumors. J Clin Oncol 2009, 27:3557-3565. 10.1200/JCO.2008.19.6683, 19546406.
74. Fasola A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin 2008, 17:1717-1734.
75. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M. Angiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66:5549-5554. 10.1158/0008-5472.CAN-05-2825, 16740688.
76. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, Frost P, Gibbons JJ. mTOR, a novel target in breast cancer: the effect of CCI 779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001, 8:249-258. 10.1677/erc.0.0080249, 11566616.
77. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759. 10.1016/j.cell.2004.12.040, 15797377.
78. Chan S, Scheulen ME, Johnston S, Mross K, Cardosa F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005, 23:5314-5322. 10.1200/JCO.2005.66.130, 15955899.
79. Ellard S, Clemons M, Gelmon KA, Norris B, Kennrcke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trial Group IND.163. J Clin Oncol 2009, 27:4536-4541. 10.1200/JCO.2008.21.3033, 19687332.
80. O'Reilly KE, Rojo F, She Q-B, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR induces upstream receptor tyrosine kinase signalling and activates Akt. Cancer Res 2006, 66:1500-1508. 10.1158/0008-5472.CAN-05-2925, 16452206.
81. Moulder SL, Rivera E, Ensor J, Gonzales-Angulo A, Christofanilli M, Booser D, Giordano S, Brewster A, Hortobagyi GN, Tran H. Phase I trial of escalating doses of weekly everolimus (RAD001) in combination with docetaxel for the treatment of metastatic breast cancer (MBC). J Clin Oncol 2009, 27(15S):abstract 1066.
82. Mayer IA, Burris HA, Bendell JC, Means-Powell J, Arteaga CL, Shyr Y, Pietenpol JA. A phase Ib trial of RAD001, an mTOR inhibitor, with weekly cisplatin and paclitaxel in patients with HER2-negative metastatic breast cancer. Cancer Res 2009, 69(Suppl):abstract 3093.
83. Carpenter JT, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, D'Amore M, Kong S, Boni J, Baselga J. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 2007, 23(16S):abstract 564.
84. Chow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl 1):abstract 6091.
85. Macaskill EJ, Bartlett JMS, White S, Renshaw L, Campbell FM, Young O, Stumm M, Faratian D, Thomas J, Barber MD, Dixon JM. The mammalian target of rapamycin inhibitor RAD001 (everolimus) in postmenopausal women with early breast cancer: results of a phase II pre-operative trial. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6092.
86. Baselga J, Semiglazow V, van Dam PA, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637. 10.1200/JCO.2008.18.8391, 19380449.
87. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 2008, 5:521-530. 10.1038/ncponc1161, 18594498.
88. Fountzilas G, Skarlos D, Wirtz RM, Dafni U, Stropp U, Pectasides D, Papakostas P, Markopoulos C, Karapanagiotis K, Polichronis A, Timotheadou E, Grimani I, Samantas E, Kosmidis P, Kalogeras KT. Prognostic value of both HER-2 and VEGF-A mRNA over-expression in primary tumors of high-risk breast cancer patients. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 6007.
89. Hurvitz SA, Pegram MD, Lin L-S, Chan DS, Allen HJ, Dichmann RA, Hagenstad CT, Barstis J, Hermann RC, Hu EH, Moroose RL, Thomas SP, Vogel CL, Ryba N, Elashoff D, Slamon DJ. Final results of a phase II trial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. Cancer Res 2009, 69(Suppl):abstract 6094.
90. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey L, Norton L, Hudis CA. Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res 2008, 14:7878-7883. 10.1158/1078-0432.CCR-08-0141, 2748748, 19047117.
91. Dickler M, Franco S, Stopeck A, Ma W, Nulsen B, Lyandres J, Melisko M, Lahiri S, Arbushites M, Koehler M, Rugo HS. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer. Cancer Res 2009, 69(Suppl 2):abstract 3133.
92. Blay J-Y, Lluch A, Gutierrez M, Martin MM, Kozloff MF, Prady C, Huang X, Chen C, Tassell V, Kern K, Verma S. Sunitinib (SU) in combination with trastuzumab (T) for the treatment of advanced breast cancer (ABC): activity and safety results from a phase II. Cancer Res 2009, 69(Suppl):abstract 201.
93. Dirix L, Canon J-L, Amadori D, Villa E, Aldrighetti D, Machiels J-P, Verkh L, Bouko Y, Kern K, Giorgetti C, Cardoso F. An exploratory study of sunitinib (SU) plus docetaxel (D) and trastuzumab (T) as first-line therapy for HER2+ advanced breast cancer (ABC). Cancer Res 2009, 69(Suppl):abstract 6088.
94. Slamon D, Gomez HL, Kabbinavar F, Amit O, Richie M, Pandite L, Goodman V. Randomized study of pazopanib - lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 2008, 26(May 20 Suppl):abstract 1016.
95. O'Regan R, Andre F, Campone M, Naughton M, Manlius C, Pylvaenaeinen I, Sahmoud T, Hurvitz S. RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial. Cancer Res 2009, 69(Suppl 2):abstract 3119.
96. Yardley DA, Seiler M, Ray-Coquard I, Melichar B, Hart L, Dieras V, Barve M, Melnyk A, Dorer D, Turner CD. Ridaforolimus (AP23573; MK-8669) in combination with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer: a multicenter phase II trial. Cancer Res 2009, 69(Suppl):abstract 3091.
97. Mayer IA, Means-Powell J, Shyr Y, Arteaga CL. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. Cancer Res 2009, 69(Suppl):abstract 3094.
98. Mayer EL, Dhakil S, Patel T, Sundaram S, Fabrian C, Kozloff M, Qamar R, Volterra F, Parmar H, Samant M, Burstein HJ. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol 2010,
99. Falchook GS, Wheler JJ, Naing A, Hong DS, Moulder SL, Piha-Paul SA, Ng CS, Jackson E, Kurzrock R. A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. J Clin Oncol 2010, 28(15S):abstract 2512.
100. Yanagisawa M, Yorozu K, Kurasawa M, Nakano K, Furugaki K, Yamashita Y, Mori K, Fujimoto-Ouchi K. Bevacizumab improves the delivery and efficacy of paclitaxel. Anticancer Drugs 2010, 21:687-694.
101. Dempke WCM, Heinemann V. Resistance to EGF-R (erb-1) and VRGF-r modulating agents. Eur J Cancer 2009, 45:1117-1128. 10.1016/j.ejca.2008.11.038, 19124237.
102. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603. 10.1038/nrc2442, 2874834, 18650835.
103. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidsen N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD. ECOG 2100: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab ECOG 2100. J Clin Oncol 2008, 26:4672-4678. 10.1200/JCO.2008.16.1612, 2653128, 18824714.
104. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231. 10.1016/j.ccr.2009.01.027, 2874829, 19249680.
105. Harbeck N, Chan A, ten Bokkel Huinink D, Chollet P, Fabiani C, Salvagni S, Pérez-Michel L, Scheeweiss A, Chlistalla A, Miles DW. No clinical evidence for increase in tumour malignant potential in patients with metastatic breast cancer treated with bevacizumab and docetaxel in the phase III AVADO study. Cancer Res 2009, 69(Suppl):abstract 6086.
106. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338. 10.1038/nrclinonc.2009.63, 19483739.
107. Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010, 102:8-18. 10.1038/sj.bjc.6605483, 20010945.
108. Sessa C, Guibal A, Del Comte G, Rüegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?. Nat Clin Pract Oncol 2008, 5:378-391. 10.1038/ncponc1150, 18560389.
109. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009, 72:217-238. 10.1016/j.critrevonc.2008.07.012, 18760935.
110. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009, 101:1044-1048. 10.1093/jnci/djp177, 2724853, 19564563.
111. Duda DG, Ancukiewicz M, Jain RK. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?. J Clin Oncol 2010, 28:183-185. 10.1200/JCO.2009.24.8021, 19949009.
112. McArthur HL, Rugo H, Paulson M, Rourke M, Traina T, Panageas K, Steingart R, Dang C, Fornier M, Park J, Moasser M, Melisko M, Sugarman S, Norton L, Hudis CA, Dickler MN. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Breast Cancer Res Treat 2007, 106(Suppl 1):abstract 3065.
113. Isaacs C, Wilkinson M, Liu MC, Ottaviano Y, Chung G, Warren R, Jennifer E-W, Cohen P, Smith KL, Novielli A, Castle J, Slack R. Phase II study of sorafenib with anastrozole to overcome resistance to aromatase inhibitors (AIs) in patients with hormone receptor positive (ER/PR+) AI resistant metastatic breast cancer (MBC). Cancer Res 2009, 69(Suppl):abstract 3090.